Why VIVUS Shares Plunged

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company VIVUS (Nasdaq: VVUS  ) sank 12% today after management said it expects its obesity drug Qsymia to be denied in Europe.

So what: VIVUS shares have more than doubled over the past year on the blockbuster promise of Qsymia, which is already approved in the U.S., but being denied access to Europe naturally lowers the drug's peak sales and market share potential. In fact, Arena Pharmaceuticals (Nasdaq: ARNA  ) , which markets competing weight loss treatment Belviq, saw its shares climb 5% today on VIVUS' regulatory setback.

Now what: While today's news is certainly disappointing for VIVUS, management fully intends to meet any additional requirements leading to Qsymia's approval in Europe. "We will work closely with the [Committee for Medicinal Products for Human Use] to address the Committee's concerns," President Peter Tam reassured investors. "VIVUS is committed to making this important medication available to obese patients in Europe." So while VIVUS remains just too speculative for average Fools, today's double-digit drop -- the stock is now off 30% from its 52-week high -- might be an attractive opportunity for biotech-savvy contrarians.

The battle of the obesity drugs is heating up, so get to know one of its key players: Arena Pharmaceuticals. Sign up today for our premium research report and get a detailed comprehensive write-up, as well as regular future updates for no additional cost! Just click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Read/Post Comments (3) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2026670, ~/Articles/ArticleHandler.aspx, 10/22/2016 10:07:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 12 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
VVUS $1.10 Down -0.01 -0.90%
VIVUS CAPS Rating: **
ARNA $1.57 Down -0.02 -1.26%
Arena Pharmaceutic… CAPS Rating: **